Galux Unveils AI Platform for Antibody Design

Galux has announced a significant advancement in AI-driven antibody design, as detailed in a recent press release. The South Korean startup's AI platform, GaluxDesign, has successfully designed antibodies for six therapeutic targets, including one without an experimentally resolved structure.

The study highlights the platform's ability to generate novel antibodies with high precision and specificity. Among the targets were PD-L1, HER2, and ALK7, with the latter lacking an experimentally resolved structure. Notably, the designed PD-L1 targeting antibody demonstrated a binding affinity comparable to the commercial therapeutic antibody Atezolizumab.

Galux's approach involved identifying binders from a yeast display single-chain variable fragment library, comprising approximately one million designed antibody sequences. This process allowed the team to screen and identify binders with varying strengths for each target, showcasing the platform's broad applicability in antibody discovery.